Unexpectedly, the expression of CASP3 was positively correlated with the sensitivity of carmustine, a drug recommended by the latest National Comprehensive Cancer Network (NCCN) for the treatment of glioma (Figure 12A). This evidence concerns the gene CASP3 and central nervous system cancer.